Durvalumab with or without tremelimumab in patients with recurrent or metastatic head and neck squamous cell carcinoma: EAGLE, a randomized, open-label phase III studyRobert L. Ferris, Lisa Licitra, Robert I. Haddad et al.|Annals of Oncology|2020Cited by 365
Durvalumab with or without tremelimumab versus the EXTREME regimen as first-line treatment for recurrent or metastatic squamous cell carcinoma of the head and neck: KESTREL, a randomized, open-label, phase III studyAmanda Psyrri, Tanguy Y. Seiwert, Jérôme Fayette et al.|Annals of Oncology|2022Cited by 144
EAGLE: A phase 3, randomized, open-label study of durvalumab (D) with or without tremelimumab (T) in patients (pts) with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC).Lisa Licitra, Robert L. Ferris, Robert I. Haddad et al.|Journal of Clinical Oncology|2019Cited by 39
Tumor Mutational Burden as a Predictor of Survival with Durvalumab and/or Tremelimumab Treatment in Recurrent or Metastatic Head and Neck Squamous Cell CarcinomaSophie Wildsmith, Ricard Mesı́a, Weimin Li et al.|Clinical Cancer Research|2023Cited by 30
Overall survival (OS) and forced vital capacity (FVC) results from the LUME-Meso study of nintedanib (N) + pemetrexed/cisplatin (PEM/CIS) vs placebo (P) + PEM/CIS in chemo-naïve patients (pts) with malignant pleural mesothelioma (MPM)Silvia Novello, Giorgio V. Scagliotti, Jakob B. Sørensen et al.|Annals of Oncology|2017Cited by 0